Lateral Canthal Lines Clinical Trial
| Verified date | July 2019 |
| Source | Allergan |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This is a postmarketing surveillance study in Korea to evaluate the safety and effectiveness of BOTOX® for lateral canthal lines (crow's feet lines) with or without simultaneous glabellar lines.
| Status | Completed |
| Enrollment | 667 |
| Est. completion date | August 14, 2017 |
| Est. primary completion date | August 14, 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Subject and Investigator decision to treat crow's feet lines with Botox® Exclusion Criteria: - None |
| Country | Name | City | State |
|---|---|---|---|
| Korea, Republic of | Dr. Robbin Clinic | Gangnam-gu | Seoul |
| Lead Sponsor | Collaborator |
|---|---|
| Allergan |
Korea, Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Participants with Adverse Events | Up to 3 months | ||
| Secondary | Investigator's Assessment of Change in Appearance of Crow's Feet Lines on a 3-Point Scale | Baseline, Up to 3 months | ||
| Secondary | Subject's Assessment of Change in Appearance of Crow's Feet Lines on a 7-Point Scale | Baseline, Up to 3 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02195687 -
BOTOX® in the Treatment of Crow's Feet Lines in China
|
Phase 3 | |
| Completed |
NCT01951742 -
Dose Finding Study In Subjects With Crow's Feet
|
Phase 2 | |
| Completed |
NCT03721016 -
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
|
Phase 3 | |
| Completed |
NCT03326856 -
ET-01 in Subjects With Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT04157686 -
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
|
Phase 3 | |
| Completed |
NCT03839693 -
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
|
Phase 2 | |
| Completed |
NCT03923634 -
Princess® RICH for the Correction of Fine Lines
|
N/A | |
| Completed |
NCT03732833 -
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
|
Phase 3 | |
| Completed |
NCT00888914 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT04143854 -
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT01358695 -
Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet
|
Phase 2 | |
| Completed |
NCT01124565 -
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
|
Phase 2 | |
| Completed |
NCT00247559 -
Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)
|
Phase 2 | |
| Completed |
NCT01809964 -
Clinical Trial to Evaluate ANT-1401 in Crow's Feet
|
Phase 2 | |
| Completed |
NCT03911102 -
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT00968825 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT04225260 -
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
|
Phase 3 | |
| Completed |
NCT01064518 -
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
|
Phase 2 | |
| Completed |
NCT00884234 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT04249687 -
Treatment of Moderate to Severe Lateral Canthal Lines
|
Phase 3 |